8EQ Stock Chart & Stats
€3.78
€0.00(0.00%)
At close: 4:00 PM EDT
€3.78
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€2.82 - €5.60
Previous CloseN/A
Volume0.00
Average Volume (3M)8.00
Market Cap
€472.56M
Enterprise Value€346.69
Total Cash (Recent Filing)€262.00M
Total Debt (Recent Filing)€26.46M
Price to Earnings (P/E)―
Beta0.56
Next Earnings
Nov 11, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.62
Shares Outstanding129,142,600
10 Day Avg. Volume0
30 Day Avg. Volume8
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.89
Price to Sales (P/S)3.20
P/FCF Ratio-73.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€4.83Price Target Upside27.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.3
Revenue Forecast (FY)€180.70M
Bulls Say, Bears Say
Bulls Say
Installed Base & Recurring Revenue ExpansionA growing installed base (3,933 units, +142 added in the quarter) and recurring revenue of 35% of LTM create durable pull-through for reagents, service and software. This installed-base-driven model supports predictable repeat sales and strengthens long-term revenue visibility and customer stickiness.
Healthy Gross Margins And Unit EconomicsSustained gross margins (mid-50s, higher on adjusted basis) indicate strong unit-level economics for instruments, products and services. Robust product margins provide room to invest in R&D and go-to-market while preserving the ability to achieve operating leverage as revenue scales over the medium term.
Conservative Balance Sheet And LiquidityVery low leverage and substantial cash (~$262M) give flexibility to fund product launches, absorb near-term cash burn, and pursue strategic initiatives without immediate refinancing. This reduces solvency risk and supports multi-quarter execution on commercialization and clinical efforts.
Bears Say
Deteriorating Profitability And Cash ConversionDeeply negative net margin (~-39%) and negative operating and free cash flow signal that revenue growth currently does not convert into cash. If losses and cash burn persist, the company may face funding pressure or delayed investments, weakening financial flexibility over the coming quarters.
Rising Operating Costs And One-time DistortionsHigher structural operating costs (R&D, S&M, G&A +15% YoY, with G&A +24% from litigation and severance) shrink operating leverage. One-time items (tariff refund, investment write-off) further obscure true margin progress, making it harder to assess sustainable profitability over the medium term.
Limited Clinical Penetration And Regulatory LimitsWeak clinical market presence and lack of U.S. clinical approvals constrain access to higher-volume hospital and diagnostic channels. This delays higher-margin, recurring clinical revenue and slows addressable-market expansion until regulatory clearances and commercial traction are achieved.
8EQ FAQ
What was Cytek Biosciences’s price range in the past 12 months?
Cytek Biosciences lowest stock price was €2.82 and its highest was €5.60 in the past 12 months.
What is Cytek Biosciences’s market cap?
Cytek Biosciences’s market cap is €472.56M.
When is Cytek Biosciences’s upcoming earnings report date?
Cytek Biosciences’s upcoming earnings report date is Nov 11, 2026 which is in 95 days.
How were Cytek Biosciences’s earnings last quarter?
Cytek Biosciences released its earnings results on Aug 05, 2026. The company reported -€0.078 earnings per share for the quarter, beating the consensus estimate of -€0.081 by €0.003.
Is Cytek Biosciences overvalued?
According to Wall Street analysts Cytek Biosciences’s price is currently Undervalued.
Does Cytek Biosciences pay dividends?
Cytek Biosciences does not currently pay dividends.
What is Cytek Biosciences’s EPS estimate?
Cytek Biosciences’s EPS estimate is -0.04.
How many shares outstanding does Cytek Biosciences have?
Cytek Biosciences has 129,142,600 shares outstanding.
What happened to Cytek Biosciences’s price movement after its last earnings report?
Cytek Biosciences reported an EPS of -€0.078 in its last earnings report, beating expectations of -€0.081. Following the earnings report the stock price went down -1.072%.
Which hedge fund is a major shareholder of Cytek Biosciences?
Currently, no hedge funds are holding shares in DE:8EQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cytek Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€4.83 (27.71% Upside)
€4.83 (27.71% Upside)
Blogger Sentiment
Bullish
DE:8EQ Sentiment 75%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
33.93%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.94%
Trailing 12-Months
Company Description
Cytek Biosciences
Cytek Biosciences, Inc. is a company dedicated to cell analysis solutions, offering advanced tools that facilitate scientific progress in both biomedical research and clinical settings. Their primary offerings include the Aurora and Northern Lights spectrum flow cytometers. These instruments conduct comprehensive cell analysis by leveraging fluorescence signatures from multiple lasers to differentiate between various fluorescent tags on individual cells. Complementing these, the Aurora Cell Sorter system utilizes full spectrum profiling technology to broaden the range of potential applications in cell analysis. Beyond instrumentation, Cytek provides essential reagents and kits. These include cFluor reagents, which are antibodies conjugated with fluorochromes, specifically designed to identify target cells for analysis on their systems. They also offer a 25-color immunoprofiling assay, a ready-to-use solution for pinpointing major human immune cell subpopulations like TBNK cells, monocytes, dendritic cells, and basophils. To streamline laboratory operations, the company offers automated micro-sampling and sample loader systems. These automated plate loaders are engineered to integrate seamlessly with the Aurora and Northern Lights systems. The intuitive SpectroFlo software accompanies these systems, simplifying the workflow from quality control through to data analysis. Cytek also provides comprehensive customer support resources. Cytek's diverse client base includes pharmaceutical and biopharmaceutical companies, academic research institutions, and clinical research organizations. The company distributes its products through a direct sales force and dedicated support teams in North America, Europe, China, and the Asia-Pacific region. Additionally, it partners with distributors and sales agents to serve markets across European, Latin American, Middle Eastern, and other Asia-Pacific countries. Originally established in 1992 as Cytoville, Inc., the company officially adopted the name Cytek Biosciences, Inc. in August 2015. Its corporate headquarters are situated in Fremont, California.
8EQ Company Deck
8EQ Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed but cautiously constructive picture: revenue growth (6% YoY) driven by strong performance in the U.S. and China, expansion of installed base, growing recurring revenue (35% of LTM), and strategic product launches (Borealis and Aurora Evo) underpin future upside. Offsetting these positives are widening GAAP losses, a Q2 adjusted EBITDA decline, regional weaknesses in EMEA and parts of APAC, rising operating expenses (including litigation-related G&A increases), and some one-time items (tariff refund, investment write-off) that cloud margin comparability. Management raised the low end of guidance and expects H2 improvement, but several challenges (regional budgetary pressures, delayed clinical penetration in the U.S., and reorganization timeline) temper near-term outlook.View all DE:8EQ earnings summaries8EQ Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€4.83
▲(27.71% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month










